Friday, 16 Nov 2018

You are here

Early Promise for Steroid-free Approach for Giant Cell Arteritis

A very small study presented at ACR18 looking at tocilizumab monotherapy in patients with a new diagnosis of giant cell arteritis has nevertheless given hope to the tantalising idea that some GCA patients might achieve drug-free remission without steroids, although broader data are required.

Dr. Shuntaro Saito and colleagues from Saitama Medical University and Keio University in Japan prospectively examined eight GCA patients prospectively over 24 months, with the patients receiving a steroid-free regimen of tocilizumab monotherapy limited to 12 months followed by 12 months of observational follow-up.

All eight patients maintained a response at 12 months. Encouragingly, in the following 12 months only two of the patients relapsed and both patients were able to restore response with recommencement of tocilizumab. No patients experienced any ischaemic events attributable to giant cell arteritis, although one patient experienced heart failure at 24 weeks leading to drug cessation while still maintaining drug response. Serial imaging of the aorta did not suggest any vascular changes during the follow-up period.

While any such approach would need to be supported by data from more patients, with long-term follow-up of efficacy and safety, these results allude to a promise of paradigm change in GCA, a disease whose current therapy is blighted by steroid-related morbidity. Tempering this promise is caution regarding inhibition of IL-6 and its presumed vascular effects without the mitigating effect of corticosteroids, and long-term follow-up are required to determine whether the risk of the most feared complications of GCA are prevented, unchanged or enhanced.

Another encouraging feature of these data was the drug-free remission achieved by most patients and the restoration of disease control with recommencement of drug in those who flared. This observation suggests that a treatment algorithm involving cessation of tocilizumab at twelve months might be appropriate in some patients. Further insights from the follow-up data from the much larger GiACTA study will help to shape this paradigm.

 

 

Add new comment

More Like This

The RheumNow Podcast – Heartbreak of Methotrexate (11.16.18)

Dr. Jack Cush reviews the news from the past week at RheumNow.com.

MMWR: Death by Firearms

The CDC's Morbidity and Mortality Weekly Report (MMWR) reports that during 2015–2016 there was a total of 27,394 firearm homicides and 44,955 firearm suicides among US residents, with 12% and 5% of events occuring in children 10–19 years.

RheumNow Weekly Podcast – 3 Wiseguy Rheumatologists (11.9.18)

Dr Jack Cush reviews the News and Journal reports from the past week on RheumNow.com.  Be sure to check out our upcoming meeting in March 2019 - RheumNow Live.

E/M Guidelines: Right Road, Wrong Direction

Last July, the Centers for Medicare & Medicaid Services (CMS) proposed new E/M guidelines for office visits with physicians. It issued the final guidelines on November 1, with a few tweaks. Implementation was delayed until 2021 (from 2019), possibly due to overwhelming opposition from physicians.

RheumNow Week in Review – The Heart Attack Report (11.2.18)

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com.